Detalhe da pesquisa
1.
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
Thyroid
; 34(3): 336-346, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226606
2.
Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
J Clin Endocrinol Metab
; 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441247
3.
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.
Front Endocrinol (Lausanne)
; 14: 1176731, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37435488
4.
Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center.
Immunotherapy
; 15(6): 417-428, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37013834
5.
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
Endocr Relat Cancer
; 28(7): 419-431, 2021 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33890870
6.
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Thyroid
; 28(10): 1243-1251, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132401
7.
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Thyroid
; 28(1): 79-87, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29161986
8.
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
J Immunother Cancer
; 6(1): 68, 2018 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29996921
9.
Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.
JCO Precis Oncol
; 22018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135166